• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    PAVmed Appoints Shaun O'Neil as Chief Operating Officer

    2/24/22 8:25:00 AM ET
    $ANGO
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ANGO alert in real time by email

    PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), today announced the appointment of Shaun O'Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O'Neil has served as PAVmed's Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 2018. He will serve on the Company's Executive Committee and as an executive officer pursuant to Section 16(a) of the Securities Exchange Act of 1934.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220224005446/en/

    PAVmed appoints Shaun O'Neil as Chief Operating Officer. (Photo: Business Wire)

    PAVmed appoints Shaun O'Neil as Chief Operating Officer. (Photo: Business Wire)

    "Mr. O'Neil has been an invaluable member of our company and its leadership team since joining us nearly four years ago, including playing a central role in our transition to a commercial enterprise," said Lishan Aklog M.D., PAVmed's Chairman and Chief Executive Officer. "He has built a solid and rapidly expanding commercial infrastructure—including sales, marketing, and market access—most notably for Lucid and its products, as well as nascent commercial teams for other commercial and near-commercial products. He has also played important roles in numerous other critical corporate initiatives, including the launch of our Lucid Test Center network, our transition to a dedicated CLIA-certified laboratory and in various business development activities. His deep involvement in operational and commercial activities across the breadth of the company make him the ideal candidate to serve as our inaugural COO, a position launched to accommodate our rapid growth to nearly one hundred employees over the past year."

    "I am energized to take on this expanded role at such an exciting time for PAVmed and its subsidiaries," said Mr. O'Neil. "We are in as strong a position as ever to execute on our strategic plan, drive commercialization of our products and grow long-term shareholder value. That strength is built on a solid balance sheet, groundbreaking technologies, and the best team in the industry. I look forward helping execute on our vision to transform PAVmed into a leading global medical technology company."

    Mr. O'Neil has served as PAVmed's Chief Commercial Officer and Executive Vice President, Business Development since 2018. Prior to PAVmed, Mr. O'Neil brought to PAVmed more than fifteen years of sales and marketing leadership, and product and business development expertise in both startup and established companies, including a particularly strong track record in growing sales and increasing market share for innovative medical devices. From 2011 to 2018 Mr. O'Neil held various sales and marketing leadership positions with AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists, interventional cardiologists, surgeons, and other physicians for the minimally invasive diagnosis and treatment of cancer and peripheral vascular disease. Prior to AngioDynamics, he served in various sales, marketing and engineering roles at Aycan Medical Systems, a privately held medical imaging company, Harris Interactive and Quality Solutions Group. Mr. O'Neil received a bachelor's degree in Business Administration from Alfred University and an M.B.A. from the Rochester Institute of Technology.

    About PAVmed

    PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics and digital health sectors. Its major subsidiary, Lucid Diagnostics Inc. (NASDAQ:LUCD), markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths. Another major subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. PAVmed's CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome is currently in limited commercial release. The product pipeline also includes the EsoCure™ Esophageal Ablation Device with Caldus™ Technology, which complements EsoGuard and EsoCheck, the NextFlo™ Intravenous Infusion Set, the PortIO™ Implantable Intraosseous Vascular Access Device, novel pediatric ear tubes, mechanical circulatory support technology and glucose monitoring. For more information, please visit www.pavmed.com, follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on LinkedIn. For detailed information on EsoGuard, please visit www.EsoGuard.com and follow us on Twitter, Facebook and Instagram.

    Forward-Looking Statements

    This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's common stock; PAVmed's Series W and Series Z warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's clinical and preclinical studies; whether and when PAVmed's products are cleared by regulatory authorities; market acceptance of PAVmed's and products once cleared and commercialized; PAVmed's ability to raise additional funding as needed; and other competitive developments. In addition, PAVmed has been monitoring the COVID-19 pandemic and the pandemic's impact on PAVmed's businesses. PAVmed expects the significance of the COVID-19 pandemic, including the extent of its effect on its financial and operational results, to be dictated by, among other things, the success of efforts to contain the pandemic and the impact of such efforts on PAVmed's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's future operations, see Part I, Item IA, "Risk Factors," in PAVmed's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report filed with the Securities and Exchange Commission. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220224005446/en/

    Get the next $ANGO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ANGO
    $LUCD
    $PAVM

    CompanyDatePrice TargetRatingAnalyst
    AngioDynamics Inc.
    $ANGO
    4/5/2024$12.00Perform → Outperform
    Oppenheimer
    AngioDynamics Inc.
    $ANGO
    9/25/2023$19.00Buy
    H.C. Wainwright
    AngioDynamics Inc.
    $ANGO
    4/17/2023$14.00 → $13.00Strong Buy → Outperform
    Raymond James
    Lucid Diagnostics Inc.
    $LUCD
    12/27/2021$16.00Buy
    Ascendiant Capital
    Lucid Diagnostics Inc.
    $LUCD
    12/15/2021$17.00 → $13.00Buy
    Needham
    Lucid Diagnostics Inc.
    $LUCD
    11/8/2021$18.00Buy
    Canaccord Genuity
    Lucid Diagnostics Inc.
    $LUCD
    11/8/2021$14.00Buy
    BTIG Research
    Lucid Diagnostics Inc.
    $LUCD
    11/8/2021$21.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ANGO
    $LUCD
    $PAVM
    SEC Filings

    See more
    • PAVmed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PAVmed Inc. (0001624326) (Filer)

      6/24/25 8:15:29 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Lucid Diagnostics Inc. (0001799011) (Filer)

      6/18/25 5:00:40 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • PAVmed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - PAVmed Inc. (0001624326) (Filer)

      6/18/25 5:00:38 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $ANGO
    $LUCD
    $PAVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31), increasing direct ownership by 40% to 565,443 units (SEC Form 4)

      4/A - Lucid Diagnostics Inc. (0001799011) (Issuer)

      5/23/25 4:14:42 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31) (SEC Form 4)

      4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

      5/22/25 4:45:49 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • New insider Tasso Partners, Llc claimed ownership of 2,574,350 shares (SEC Form 3)

      3 - PAVmed Inc. (0001624326) (Issuer)

      3/14/25 7:53:09 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care

    $ANGO
    $LUCD
    $PAVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31), increasing direct ownership by 40% to 565,443 units (SEC Form 4)

      4/A - Lucid Diagnostics Inc. (0001799011) (Issuer)

      5/23/25 4:14:42 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31) (SEC Form 4)

      4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

      5/22/25 4:45:49 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • SVP Quality and Regulatory Nighan Warren Jr bought $5,285 worth of shares (868 units at $6.09), increasing direct ownership by 2% to 45,877 units (SEC Form 4)

      4 - ANGIODYNAMICS INC (0001275187) (Issuer)

      10/10/24 3:22:57 PM ET
      $ANGO
      Medical/Dental Instruments
      Health Care

    $ANGO
    $LUCD
    $PAVM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

      Private placement yields $2.5 million from the sale of Veris Health common stock at a $35 million pre-money valuation. NEW YORK, June 24, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary, Veris Health Inc. ("Veris"), today announced the completion of a private placement equity financing directly into Veris, yielding $2.5 million in proceeds (gross and net). This supplements a prior $2.4 million financing completed earlier this year.

      6/24/25 8:01:00 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism

      Multi-center, multi-national study builds on existing U.S. PE Clearance and CE Mark to assess mechanical thrombectomy treatment and long-term functional outcomes in intermediate-risk PE patients across Europe AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving patient quality of life, today announced the first patient has been enrolled in the RECOVER-AV clinical trial, a prospective, multi-center, multi-national, single-arm study evaluating the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in the treatment of acute

      6/23/25 8:00:00 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

      Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery network NEW YORK, June 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that Hoag, a nationally-recognized regional healthcare delivery network, has launched a comprehensive, integrated esophageal precancer testing program using Lucid Diagnostics' EsoGuard® Esophageal DNA Test. Lucid will partner with Hoag to offer EsoGuard testing across its digestive health, prim

      6/18/25 12:02:00 PM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $ANGO
    $LUCD
    $PAVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AngioDynamics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded AngioDynamics from Perform to Outperform and set a new price target of $12.00

      4/5/24 7:36:59 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • H.C. Wainwright initiated coverage on AngioDynamics with a new price target

      H.C. Wainwright initiated coverage of AngioDynamics with a rating of Buy and set a new price target of $19.00

      9/25/23 8:09:50 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care
    • AngioDynamics downgraded by Raymond James with a new price target

      Raymond James downgraded AngioDynamics from Strong Buy to Outperform and set a new price target of $13.00 from $14.00 previously

      4/17/23 7:20:48 AM ET
      $ANGO
      Medical/Dental Instruments
      Health Care

    $ANGO
    $LUCD
    $PAVM
    Leadership Updates

    Live Leadership Updates

    See more
    • Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

      NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Lucid is joining these importa

      5/27/25 7:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

      Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements.  As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remain

      9/16/24 4:30:00 PM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

      Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing

      5/7/24 7:39:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $ANGO
    $LUCD
    $PAVM
    Financials

    Live finance-specific insights

    See more
    • PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

      Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and late preclinical stage assets Conference call and webcast to be held today, May 15th, at 8:30 AM EDT NEW YORK, May 15, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical

      5/15/25 8:01:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa

      5/1/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2025 finan

      4/30/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $ANGO
    $LUCD
    $PAVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lucid Diagnostics Inc.

      SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

      12/12/24 4:30:32 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      11/14/24 10:02:46 AM ET
      $PAVM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by PAVmed Inc.

      SC 13G - PAVmed Inc. (0001624326) (Subject)

      9/23/24 8:46:15 PM ET
      $PAVM
      Medical/Dental Instruments
      Health Care